Stent a rilascio di farmaco: Dai risultati degli studi clinici ai modelli di impatto economico-sanitario nella realtà Italiana

Translated title of the contribution: Drug-releasing stent: From the result of the clinical studies to the models of economic-health impact in the Italian reality

Giuseppe Sangiorgi, Peppa Rodamni, Flavio Airoldi, Antonio Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Several studies with drug-eluting stents (DES) have demonstrated dramatic reductions in restenosis rates compared with bare metal stents (BMS). Although the clinical benefits of DES are increasingly evident, important concerns about their costs have been raised. Most data regarding the impact of restenosis on long-term costs after percutaneous coronary intervention (PCI) are derived from clinical trials. These studies demonstrate that there is no single cost or economic burden of restenosis; these values vary substantially according to the specific patient population under investigation and to the healthcare system reality where they are applied. In the present study we propose an economic interactive decision model which was applied to the Italian healthcare system, considering the different reimbursement rates of the Italian regions for DES and for both PCI and coronary artery bypass surgical interventions (CABG). The aim of this model was to simulate the impact of DES introduction after potential complete reimbursement by the national healthcare system, hypothesizing the usage of 1.4 stent per patient in case of single vessel disease and 2.4 stents in case of multivessel disease, and utilizing the TAXUS IV rate of revascularization for reintervention costs calculation and the ARTS-I study for CABG costs. For a low risk patients' population, the mean cost of a procedure with DES was 6% greater than utilizing BMS (€ 8125 for DES vs € 7651 for BMS). However, this percentage was reduced in case of diabetic patients (+4%), long lesions (+2%) and was favourable for small vessels (-3%). In addition, in case of multivessel disease with conversion from CABG to DES, the 12 months cost per patients was reduced of around 30% (€ 10170 for PCI vs € 14 584 for CABG). This model suggests that national helthcare system may save 2.1% of the total costs (€ 18.60 millions) if 60% of revascularization procedures converts to total DES utilization and 15% from CABG to PCI with DES.

Translated title of the contributionDrug-releasing stent: From the result of the clinical studies to the models of economic-health impact in the Italian reality
Original languageItalian
Pages (from-to)145-156
Number of pages12
JournalItalian Heart Journal Supplement
Volume6
Issue number3
Publication statusPublished - Mar 2005

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Drug-releasing stent: From the result of the clinical studies to the models of economic-health impact in the Italian reality'. Together they form a unique fingerprint.

Cite this